Asaadi Faezeh, Faeghi Fariborz, Ashrafi Farzad, Sanei Taheri Morteza
Department of Radiology Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neurology Brain Mapping Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Basic Clin Neurosci. 2021 Nov-Dec;12(6):729-736. doi: 10.32598/bcn.2021.1560.1. Epub 2021 Nov 1.
Despite various imaging methods, the accurate diagnosis of numerous neurodegenerative diseases remains controversial. Using advanced imaging techniques, like diffusion-weighted imaging, can help the early detection of Multiple Sclerosis (MS) and evaluation of the treatment efficacy in these patients.
In total, 24 MS patients with acute attack and 30 healthy subjects were considered in our study. Region of Interest (ROI) was defined for acute and chronic plaques and Normal-Appearing White Matter (NAWM) in the patients' group. In the normal group, ROI only was mapped in the white matter in the same regions of the patient. All MS patients were receiving Methylprednisolone for 3 to 5 days. The rate of clinical disability in these patients was also evaluated based on the Expanded Disability Status Scale (EDSS) index. Finally evaluate changes of ADC values of plaques and NAWM before and after treatment.
The Apparent Diffusion Coefficient (ADC) values of acute plaques, the ADC values of NAWM, the number of enhancement in T1w, and EDSS values suggested a significant difference after treatment compared to before treatment. However, the ADC values of chronic plaques revealed no significant difference after treatment. There was a significant positive correlation between the difference in EDSS values before and after treatment.
The study results demonstrated that using diffusion technique and ADC values analysis is a proper non-invasive method for MS diagnosis and evaluating treatment efficacy in these patients.
The obtained results suggested that the mean ADC for acute plaques and normal white matter significantly decreased after methylprednisolone treatment.Our study indicated a strong correlation between variations in EDSS, the mean ADC for acute plaques, and normal white matter.The collected results indicated that the number of enhanced plaques decreased after treatment. Besides, there was a positive correlation between its variations and EDSS.
Multiple Sclerosis (MS) is a common inflammatory disorder of the central nervous system that could result in physical and mental disabilities in patients. Disease progression usually manifests as a series of attacks. Although there is no proven cure for MS, different treatment strategies aim to modify the cause of the disease, manage its symptoms, and prevent and postpone disability. The most common therapy in acute attacks is using corticosteroid drugs. In addition to the treatment, evaluating the success rate of treatment was also challenging. Historically, clinical assessments method (e.g. EDSS) have been used as the baseline for measuring the therapy's efficiency. Several supplementary methods, including imaging techniques, are introduced to address this issue. Conventional MRI imaging with injection has been widely accepted to assess the treatment. However, because of the modest sensitivity of conventional MRI to detect subtle pathological changes, there is a poor correlation between its findings and patients' disability. This study moved from conventional MRI to advanced techniques, such as DWI and its quantitative index named ADC value. This technique can provide information about microstructural changes in MS patients. This method does not require injection, so there are no probable adverse effects and lower scan time. This study emphasizes changes in ADC value and EDSS before and after treatment with methylprednisolone. Our results suggested s that ADC values and EDSS after treatment are significantly different from their typical values. ADC values can be used as a biomarker to evaluate treatment efficiency, yet it is not objective enough to use it alone. So, the combination of DWI imaging with conventional methods might be beneficial in assessing treatment efficiency in MS patients.
尽管有多种成像方法,但众多神经退行性疾病的准确诊断仍存在争议。使用先进的成像技术,如扩散加权成像,有助于早期检测多发性硬化症(MS)并评估这些患者的治疗效果。
本研究共纳入24例急性发作的MS患者和30名健康受试者。在患者组中,为急性和慢性斑块以及正常外观白质(NAWM)定义感兴趣区域(ROI)。在正常组中,仅在患者相同区域的白质中绘制ROI。所有MS患者均接受甲基强的松龙治疗3至5天。还根据扩展残疾状态量表(EDSS)指数评估这些患者的临床残疾率。最后评估治疗前后斑块和NAWM的表观扩散系数(ADC)值的变化。
与治疗前相比,急性斑块的表观扩散系数(ADC)值、NAWM的ADC值、T1加权像上的强化次数以及EDSS值在治疗后显示出显著差异。然而,慢性斑块的ADC值在治疗后未显示出显著差异。治疗前后EDSS值的差异之间存在显著正相关。
研究结果表明,使用扩散技术和ADC值分析是诊断MS以及评估这些患者治疗效果的一种合适的非侵入性方法。
获得的结果表明,甲基强的松龙治疗后急性斑块和正常白质的平均ADC值显著降低。我们的研究表明EDSS变化、急性斑块的平均ADC值和正常白质之间存在强相关性。收集的结果表明治疗后强化斑块数量减少。此外,其变化与EDSS之间存在正相关。
多发性硬化症(MS)是一种常见的中枢神经系统炎性疾病,可导致患者身体和精神残疾。疾病进展通常表现为一系列发作。虽然MS尚无经证实的治愈方法,但不同的治疗策略旨在改变疾病病因、控制症状以及预防和延缓残疾。急性发作时最常见的治疗方法是使用皮质类固醇药物。除了治疗外,评估治疗成功率也具有挑战性。从历史上看,临床评估方法(如EDSS)一直被用作衡量治疗效果的基线。为解决这一问题,引入了包括成像技术在内的几种辅助方法。注射对比剂的传统MRI成像已被广泛用于评估治疗。然而,由于传统MRI检测细微病理变化的敏感性有限,其结果与患者残疾之间的相关性较差。本研究从传统MRI转向先进技术,如扩散加权成像(DWI)及其定量指标表观扩散系数(ADC)值。该技术可以提供有关MS患者微观结构变化的信息。这种方法不需要注射,因此没有可能的不良反应且扫描时间较短。本研究强调甲基强的松龙治疗前后ADC值和EDSS的变化。我们的结果表明治疗后的ADC值和EDSS与它们的典型值有显著差异。ADC值可作为评估治疗效果的生物标志物,但单独使用不够客观。因此,DWI成像与传统方法相结合可能有助于评估MS患者的治疗效果。